InvestmentUpdated on 21 October 2025
Advanced Therapies for liver diseases
CEO at Servatrix
Madrid, Spain
About
Liver fibrosis in the form of MASH is the most common liver disorder worldwide, will affect approximately 25% of world´s population (1 in 4)
TAM of 27 B
Currently, only one drug has received provisional FDA approval for MASH after 1 year of clinical trial. with some concerns: results after completion of the 5-year clinical trial / optimization of dosing and timing / long term safety / very expensive / not covered by Health Systems for a chronic treatment
But oru approach in totally new, Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of multiple defensive genes.NRF2 makes heterodimers with small MAFs and activates genes containing the Antioxidant response Element (ARE).
Organisation
Similar opportunities
Product
- Industry
- Providers
- Environment
- Circular Economy
- Commercial partners
ISRAEL SOARES
CEO at GreenWay Decarbonization Solutions
Vitória - ES, Brazil
Investment
Looking for bussiness angel interested in Gym Machinery, Sport medicine and rehabilitation market
- Startup
- Healthcare
- Seed and Development
- Industrial Equipment and Machinery
Alberto Jardón Huete
Head of Assistive and Rehabilitation Lab- RoboticsLab UC3M at ROBOKINETICS
Madrid, Spain
Service
Computational linguistics professional services for AI solutions
- Telco
- Energy
- Testing
- Research
- Advisory
- Analysis
- Industry
- Aerospace
- Consulting
- Healthcare
- Development
- Environment
- Circular Economy
- Security & Defence
Pablo Haya
Business and Language Analytics Director at IIC
Madrid, Spain